Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dottikon ES Holding AG (DESN.SW)
Dottikon, AG, CH
Dottikon ES Holding AG manufactures and sells performance chemicals, intermediates, and active pharmaceutical ingredients for the chemical, biotech, and pharmaceutical maceutic industries in Europe, Switzerland, the United States, and Asia. The company’s chemicals and intermediates include amines, anilines, azaindoles, benzimidazoles, benzoic acid derivatives, benzyl compounds, boron building blocks, chiral compounds, cyclohexane derivatives, cyclopropyl building blocks, indazoles, indoles, N-heterocycles, nitrate esters, nitroaromatic compounds, O-heterocycles, phenols and anisoles, and pyridine building blocks. It also offers Dottisol, an isosorbide dimethyl ether for application as a solubility enhancer in cosmetic, pharma, and agro products, as well as a performance additive in various industries. In addition, the company is involved in recycling and waste treatment which includes the recycling, thermal recovery, and high-temperature incineration of waste streams, as well as wastewater treatment and purification activities. Further, it offers chemical custom manufacturing, nitrosamine risk assessment, and containment services; and performance chemicals, including aromatic and alicyclic diamines, bio-based organosilanes, and phlegmatized azides. The company was founded in 1913 and is headquartered in Dottikon, Switzerland. Dottikon ES Holding AG is a subsidiary of EVOLMA Holding AG.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.18% | -15.51% | -15.40% | -14.79% | -14.43% | -15.87% | +11.55% | +17.68% | +45.39% | +844.79% | +2,807.77% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+11.2% ★ Q1'26: +33.8% (vs Q1'24)
-
EPS growth Chemicals - Specialty: +13.2%-2.0% Q1'26: +29.4% (vs Q1'24)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+19.8% Q1'26: -2.7% (vs Q1'24)
-
EBIT margin Chemicals - Specialty: +8.8%+27.9% ★ Q1'26: +24.2% (vs Q1'24)
-
ROIC Chemicals - Specialty: +5.6%+10.2% ★ Q1'26: +19.4% (vs Q1'24)
-
Share dilution Chemicals - Specialty: +0.1%+0.0% Q1'26: +0.1% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×0.86× ★ Q1'26: 0.44× (vs Q1'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2007 actual |
Mar 2008 actual |
Mar 2009 actual |
Mar 2010 actual |
Mar 2011 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 2 Rev. Ana. 1 EPS Ana. |
Mar 2027 2 Rev. Ana. 1 EPS Ana. |
Mar 2028 2 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
136.83M
est: 140.98M (-2.9%)
|
141.95M
est: 146.16M (-2.9%)
|
150.25M
est: 157.32M (-4.5%)
|
113.12M
est: 163.77M (-30.9%)
|
80.08M
est: 173.03M (-53.7%)
|
319.45M
est: 334.21M (-4.4%)
|
326.27M
est: 371.61M (-12.2%)
|
385.23M
est: 340.40M (+13.2%)
|
459.08M
458.49M – 459.66M
+34.9% YoY
|
560.34M
557.69M – 562.99M
+22.1% YoY
|
688.35M
658.93M – 717.78M
+22.8% YoY
|
717.78M
699.34M – 736.21M
+4.3% YoY
|
| EBITDA |
33.14M
est: 51.92M (-36.2%)
|
34.29M
est: 52.77M (-35.0%)
|
39.18M
est: 56.80M (-31.0%)
|
26.08M
est: 42.01M (-37.9%)
|
5.81M
est: 64.04M (-90.9%)
|
116.65M
est: 123.09M (-5.2%)
|
114.05M
est: 136.86M (-16.7%)
|
144.73M
est: 125.37M (+15.4%)
|
169.07M
168.86M – 169.29M
+34.9% YoY
|
206.37M
205.39M – 207.34M
+22.1% YoY
|
253.51M
242.68M – 264.35M
+22.8% YoY
|
264.35M
257.56M – 271.14M
+4.3% YoY
|
| EBIT |
17.50M
est: 41.23M (-57.6%)
|
23.54M
est: 41.90M (-43.8%)
|
29.15M
est: 45.10M (-35.4%)
|
13.01M
est: 27.36M (-52.4%)
|
-8.86M
est: 50.85M (-117.4%)
|
96.33M
est: 97.73M (-1.4%)
|
93.41M
est: 133.53M (-30.0%)
|
122.70M
est: 122.32M (+0.3%)
|
164.96M
164.75M – 165.17M
+34.9% YoY
|
201.35M
200.40M – 202.31M
+22.1% YoY
|
247.35M
236.78M – 257.93M
+22.8% YoY
|
257.93M
251.30M – 264.55M
+4.3% YoY
|
| Net Income |
17.08M
est: 150.82M (-88.7%)
|
20.21M
est: 189.36M (-89.3%)
|
22.11M
est: 259.49M (-91.5%)
|
12.64M
est: 23.35M (-45.9%)
|
-7.06M
est: 445.00M (-101.6%)
|
87.71M
est: 81.95M (+7.0%)
|
80.63M
est: 85.70M (-5.9%)
|
105.58M
est: 98.98M (+6.7%)
|
120.57M
116.54M – 124.59M
+21.8% YoY
|
148.80M
143.88M – 153.82M
+23.4% YoY
|
180.23M
174.27M – 186.32M
+21.1% YoY
|
206.75M
199.84M – 213.65M
+14.7% YoY
|
| SGA |
11.22M
est: 1.55M (+621.5%)
|
47.35M
est: 1.58M (+2,897.3%)
|
49.59M
est: 1.70M (+2,816.1%)
|
43.82M
est: 52.41M (-16.4%)
|
—
est: 1.92M (-100.0%)
|
2.15M
est: 3.68M (-41.7%)
|
5.86M
est: 4.10M (+43.0%)
|
6.15M
est: 3.75M (+64.0%)
|
5.06M
5.06M – 5.07M
+34.9% YoY
|
6.18M
6.15M – 6.21M
+22.1% YoY
|
7.59M
7.27M – 7.91M
+22.8% YoY
|
7.91M
7.71M – 8.12M
+4.3% YoY
|
| EPS |
1.38
est: 10.91 (-87.4%)
|
1.64
est: 13.77 (-88.1%)
|
1.87
est: 18.87 (-90.1%)
|
1.02
est: 24.35 (-95.8%)
|
-0.57
est: 32.04 (-101.8%)
|
6.35
est: 5.93 (+7.1%)
|
5.84
est: 6.30 (-7.3%)
|
7.64
est: 7.16 (+6.7%)
|
8.72
8.43 – 9.01
+21.8% YoY
|
10.77
10.41 – 11.13
+23.5% YoY
|
13.04
12.61 – 13.48
+21.1% YoY
|
14.96
14.46 – 15.46
+14.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-29 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-15 | B- | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.12% | 1.38M | 0.40% |
| 2 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.07% | 234.2K | 0.23% |
| 3 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.07% | 234.2K | 0.23% |
| 4 | iShares MSCI Europe Small-Cap ETF IEUS | 0.07% | 114.6K | 0.41% |
| 5 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.06% | 2.20M | 0.30% |
| 6 | iShares Core SPI(R) ETF (CH) CHSPI.SW | 0.05% | 3.20M | 0.10% |
| 7 | Schwab International Small-Cap Equity ETF SCHC | 0.04% | 2.19M | 0.06% |
| 8 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.03% | 70.4K | 0.83% |
| 9 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.03% | 4.24M | 0.40% |
| 10 | iShares International Small-Cap Equity Factor ETF ISCF | 0.03% | 192.8K | 0.24% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Markus Blocher Chem. sc. nat. | Chairman, Chief Executive Officer & MD | 660.0K | — |
| Karin Krause | Head of Human Resources | — | female |
| Kurt Tripolt | Head of Recruiting & Administration | — | male |
| Marlene Born Eidg. | Chief Financial Officer | — | female |
| Robert Dahinden | Head of Production | — | — |
| Rolf Jens Schaller | Head of Quality Management | — | — |
| Stephan Kirschbaum Chem. rer. nat. | Head of Business Development | — | — |
| Andreas Müller | Head of Processes & Technologies | — | — |
| Thomas Rosatzin | Head of Purchasing | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DESN.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
